Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 767Lung Neoplasms 340Ovarian Neoplasms 318Breast Neoplasms 277Fallopian Tube Neoplasms 158Triple Negative Breast Neoplasms 144Small Cell Lung Carcinoma 142Neoplasms 134Squamous Cell Carcinoma of Head and Neck 122Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 77Esophageal Neoplasms 71Uterine Cervical Neoplasms 70Adenocarcinoma of Lung 69Neuroblastoma 55Central Nervous System Neoplasms 52Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Brain Neoplasms 48Recurrence 47Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Lymphoma, Non-Hodgkin 31

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2sintilimab 1osimertinib 1cemiplimab 1Surgical Procedures, Operative 1Platinum Compounds 1Pemetrexed 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Resectable Non-small Cell Lung Cancer × Carboplatin × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Akeso

Phase 2 Active not recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡